Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Debt: 2022-2024

Historic Non-Current Debt for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $43.9 million.

  • Taysha Gene Therapies' Non-Current Debt rose 18.34% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 18.34%. This contributed to the annual value of $43.9 million for FY2024, which is 8.48% up from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Non-Current Debt is $43.9 million, which was up 8.48% from $40.5 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Non-Current Debt registered a high of $43.9 million during FY2024, and its lowest value of $38.0 million during FY2022.
  • Moreover, its 3-year median value for Non-Current Debt was $40.5 million (2023), whereas its average is $40.8 million.
  • Data for Taysha Gene Therapies' Non-Current Debt shows a peak YoY increased of 8.48% (in 2024) over the last 5 years.
  • Taysha Gene Therapies' Non-Current Debt (Yearly) stood at $38.0 million in 2022, then increased by 6.69% to $40.5 million in 2023, then rose by 8.48% to $43.9 million in 2024.